Celltrion applies approval of antibody biosimilar ‘Herzuma’ to EMA
On the 27th of October(local time), Celltrion announced the application for approval of the antibody biosimilar to treat breast cancer, ‘Herzuma,’ was officially accepted at the European Medicines Agency(EMA). The original product of Herzuma is the U.S. Roche’s antibody, ‘Herceptin(generic name: ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
